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Abstract Hippocampal sclerosis (HS) is character-
ized by selective neuronal loss and gliosis in CA1 and
the subiculum and has been associated with several dis-
orders, including Alzheimer’s disease, frontotemporal
lobar degeneration with ubiquitin immunoreactive
inclusions (FTLD-U), vascular dementia and some
tauopathies. In some cases, HS is not associated with
other degenerative pathologies. Such cases are some-
times referred to as HS dementia (HSD). DiVerences
between HSD and HS in the setting of FTLD-U have
not been systematically investigated. To this end, eight
cases of HSD and ten cases of HS associated with
FTLD-U were studied with Nissl and periodic acid-
SchiV stains to assess neuronal loss and corpora amyla-
cea, respectively. Sections were immunostained with
antibodies to glial Wbrillary acidic protein, HLA-DR
and synaptophysin and immunoreactivity was mea-
sured with image analysis in CA1 and the subiculum of
each case. Additionally, sections were immunostained
with antibodies to 4-R tau to determine the presence of
argyrophilic grains. HSD was diVerent from HS associ-
ated with FTLD-U. SpeciWcally, it was more common
in the elderly, and it was associated with more marked
neuronal and synaptic loss and with greater reactive
gliosis. Corpora amylacea tended to be more frequent
in HSD than in FTLD-U, but there was no diVerence
in frequency of argyrophilic grains.
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Introduction
Hippocampal sclerosis (HS) is deWned as selective neu-
ronal loss and gliosis of CA1 and the subiculum of the
hippocampus. Its prevalence in demented patients
ranges from 2.8 to 13% [4–6, 15, 25, 26]. It is associated
with several other disorders, including Alzheimer’s dis-
ease (AD), frontotemporal lobar degeneration with
ubiquitin immunoreactive inclusions (FTLD-U), vas-
cular dementia, dementia with Lewy bodies and some
tauopathies. Occasionally, HS has been reported as an
independent pathologic explanation for dementia, the
so-called HS dementia (HSD). The reported preva-
lence of HSD ranges from 0.4 to 2% [2, 4, 15, 27].
The etiology of HS is uncertain in most cases, but it
is hypothesized to be due to either hypoxic-ischemic
injury or to neurodegeneration of selectively vulnera-
ble neuronal populations in CA1 and the subiculum [4,
36]. An hypoxic-ischemic origin is supported by the
known deWcient hippocampal vascular supply [8] and
the fact that CA1 hippocampal neurons have a higher
susceptibility to hypoxia due to their concentration of
glutamate receptors, which may be involved in excito-
toxic cell death [30]. Further arguments in favor of this
theory are the association of hypoxic-ischemic episodes
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in patients with HS [12, 34, 37] and the increased prev-
alence of cardiac [3, 10, 29] and cerebrovascular dis-
ease [11,  12,  26,  35] in cases of HS of presumed
hypoxic-ischemic origin.
Since many cases of HS do not have histories of
hypoxia or ischemia [2, 10, 12, 15, 27], cardiac disease
[2, 11, 12, 27] or cerebrovascular accidents [10, 27], a
degenerative cause is also proposed. This hypothesis is
supported by the frequent association of HS with
degenerative dementias like AD [3, 4, 12, 15, 16, 27, 29]
and FTLD-U [3, 4, 13, 15, 19, 22, 24, 29] and the less
frequently with tauopathies, mainly argyrophilic grain
disease (AGD) and FTDP-17 [5, 12, 17].
The aim of this study was to compare the pathologi-
cal characteristics of HSD versus HS in the setting of
FTD-U.
Materials and methods
The Mayo Clinic Jacksonville brain bank database
between 1998 and 2005 of individuals with dementia or
degenerative neuropathology (N = 1,487) was screened
for specimens with HS that had complete neuropatho-
logic evaluations. This evaluation included description
of gross and microscopic Wndings, as well as quantita-
tive information about Alzheimer type pathology. Spe-
ciWcally, the reports include counts of senile plaques
and neuroWbrillary tangles in six cortical sections, four
sectors of the hippocampus, two regions of the amyg-
dala, as well as subcortical regions with thioXavin-S
Xuorescent microscopy. It also involves immunohisto-
chemistry for tau, -synuclein and ubiquitin, as appropri-
ate, as previously described [4]. A Braak neuroWbrillary
tangle stage was assigned to all cases based upon the
distribution of neuroWbrillary tangles with thioXavin-S
Xuorescent microscopy, as previously described [4, 14,
21, 31, 33].
HS was detected in 103 cases; in 95 cases (92%) it
was associated with a primary degenerative disease
process, mostly AD (36; 18 men and 18 women;
85 § 5 years of age) and FTLD-U (44; 23 men and 21
women; 75 § 12 years of age; P < 0.01 compared to
AD). HS was detected in about 5% of AD cases (36
of 637) and 75% of FTLD-U cases (44 of 59). The
remainder of cases included HS in the setting of a wide
range of pathologies, including Lewy body disease,
progressive supranuclear palsy, corticobasal degenera-
tion and multiple system atrophy. In eight cases, HS
was not associated with degenerative pathology.
For this study, 18 cases were selected for further
study and placed in one of two groups. The Wrst group
of eight cases was operationally termed HSD; most
HSD cases (75%) were associated with evidence of
cerebrovascular disease. When compared to a control
group of 30 cases from the same brain bank matched
for age, sex and Braak stage, cerebrovascular disease
was detected in 80% of the controls, a frequency simi-
lar to that in HSD. Therefore, we could not necessarily
assume that the HS was due to hypoxic-ischemic
causes. In all HSD cases, FTLD-U was ruled out with
ubiquitin immunohistochemistry. The second group
(“FTLD-U HS”) included 10 cases of HS associated to
FTLD-U. None of the FTLD-U HS cases had patho-
logic evidence of cerebrovascular disease or other
pathologic processes, and HS was assumed to be
related to FTLD.
In all 18 cases other pathologic processes, such as
progressive supranuclear palsy, corticobasal degenera-
tion or Lewy body disease were absent. Alzheimer
type pathology was minimal. None of the cases in
either the HSD or FTLD-U HS group had a Braak
neuroWbrillary tangle stage greater than IV. In none of
the cases could neuronal loss in the hippocampus be
attributed to neuroWbrillary tangles, since none had
many extracellular (“ghost”) neuroWbrillary tangles.
Medial temporal tauopathy due to AGD was not a
basis for exclusion, and all cases were screened for this
age-related pathology with immunohistochemistry
using isotype-speciWc tau antibodies, as previously
reported [17].
Coronal sections of the posterior hippocampus at
the level of the lateral geniculate nucleus were cut at
a thickness of 5 m. Sections were stained with Nissl
and periodic acid-SchiV (PAS) stains. Sections were
immunostained on a DAKO Autostainer with anti-
bodies to HLA-DR, glial Wbrillary acidic protein
(GFAP), 4R tau and synaptophysin using procedures
similar to those reported previously [23]. The follow-
ing primary antibodies were used: anti-GFAP (GA-5,
monoclonal, 1:1,000, Biogenex, San Ramon, CA),
anti-HLA-DR (LN3, monoclonal, 1:100, eBioscience,
San Diego, CA), anti-4R tau (ET3, monoclonal, 1:25,
Dr. Peter Davies, Albert Einstein College of Medi-
cine, Bronx, NY) and anti-synaptophysin (EP10,
monoclonal, 1: 10, Dr. Peter Davies, Albert Einstein
College of Medicine, Bronx, NY). For antigen retrieval,
slides were steamed in distilled water for 30 min. For
ET3 immunostaining, which has been shown to be
a sensitive and speciWc method for detecting AGD
[17,  32], slides were also pretreated in 99% formic
acid for 30 min.
The degree of neuronal loss in the subiculum, CA1,
CA2/3, CA4 (end plate) and dentate gyrus was evalu-
ated on Nissl stained sections using a three-point rating
scale: 0, absent; 1, mild-to-moderate; and 2, marked.Acta Neuropathol (2007) 113:245–252 247
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PAS staining was used to assess the density of corpora
amylacea. Corpora amylacea were deWned as round,
PAS-positive structures in the neuropil, perivascular,
subpial and subependymal areas [7]. Presence of cor-
pora amylacea throughout the hippocampus was
graded on a four-point scale: 0, absent; 1, sparse; 2,
moderate; and 3, many.
To assess astrocytic, microglial and synaptic immuno-
reactivity, sections immunostained for GFAP, HLA-DR
and synaptophysin were used. Standardized, non-
overlapping, digital images of the pyramidal layer of
CA1 and subiculum were taken under a 40£ objective
on a light microscope. Immunoreactivity was quanti-
Wed as a percentage area using MetaMorph software,
version 6.3r0 (Molecular Devices, Sunnyvale, CA).
Four-R (4R) tau immunostained slides were used to
determine the presence of AGD. Cases were consid-
ered to have AGD if they had small dot- or comma-
like argyrophilic lesions in neuronal processes of the
pyramidal layer and the entorhinal cortex, as well as
coiled bodies in temporal white matter, which are the
same criteria used in other studies [31].
Clinical and neuropathologic records were reviewed
to collect data on age, sex, Braak neuroWbrillary tangle
stage, brain weight and macroscopic and microscopic
neuropathology  Wndings at autopsy. The recorded
gross Wndings at autopsy were lobar, hippocampal and
mammillary body atrophy. The remarkable micro-
scopic Wndings were vascular pathology, ischemic brain
injury and white matter disease.
DiVerences between the two groups in age, Braak
stage, brain weight, corpora amylacea, neuronal loss
and glial and synaptic immunoreactivity pathology
were analyzed with unpaired t test and Mann–Whitney
U tests depending upon the variable. Fisher’s exact test
was used to compare sex, presence of AGD and
remarkable pathologic Wndings. The statistical analyses
were performed using Sigma Stat for Windows, version
3.11 (Systat Software, Richmond, CA) and the signiW-
cance levels were set at P <0 . 0 5 .
Results
A summary of the demographic and neuropathologic
Wndings of the 18 cases included in this study is pre-
sented in Table 1. A comparison of the two groups is
presented in Table 2. The cases with HSD had an
older age of death than those with FTLD-U HS (84
vs. 65, P = 0.001). In the HSD group, six of eight
cases were men, while four of six cases in the FTLD-
U HS group were men, but this diVerence was not
signiWcant.
Neuropathologic Wndings
The Braak neuroWbrillary tangle stage was signiWcantly
greater in HSD than in FTLD-U HS. The brain weight
was also greater in HSD than in FTLD-U HS. Cortical
atrophy was more frequent in FTLD-U HS than HSD
in frontal (100% vs. 25%), medial temporal (78% vs.
13%), lateral temporal (67% vs. 33%) and parietal
lobes (67% vs. 17%). The diVerence reached statistical
signiWcance in frontal and medial temporal regions.
Both groups showed marked gross atrophy of the hip-
pocampal formation and mammillary body.
In this comparative study, cerebrovascular pathol-
ogy was virtually limited to the HSD group. Athero-
sclerosis of large vessels at the base of the brain was
present in seven of eight HSD cases. Three had mini-
mal, 1 had mild (occluding less than 50% of the lumen)
and 3 had moderate atherosclerosis (occluding between
50% and 75% of the lumen). Arteriosclerosis deWned
by presence of hyalinosis of the media and adventitial
Wbrosis of small (<100 m diameter) vessels was pres-
ent in 5 (63%) cases and cerebral amyloid angiopathy
(CAA) was present in 4 (50%) of 8 HSD. Three (30%)
cases of FTLD-U HS had minimal atherosclerosis.
None of the cases of this group had signiWcant arteriol-
osclerosis or evidence of CAA.
Ischemic brain injury was present in six of eight
HSD cases, but in none of the FTLD-U HS cases. The
eight HSD cases included 3 (38%) with lacunar inf-
arcts, 4 (50%) with microscopic infarcts and 5 (63%)
with microscopic foci of ischemic gliosis.
Most cases, independent of their group, showed
white matter pathology deWned by rarefaction and
attenuation of white matter, associated with dilated
perivascular spaces, loss of myelinated Wbers and glio-
sis. These Wndings were present in the periventricular
white matter in seven of eight HSD cases. In three of
these cases more diVuse white matter pathology was
also present, involving the centrum semiovale. All of
the cases with FTLD-U HS showed white matter
pathology that followed the distribution of the cortical
atrophy.
Two of the HSD cases (P4 and P7) had only minimal
atherosclerosis and CAA, which was probably insuY-
cient to cause hippocampal hypoperfusion, but both
cases had a history of coronary artery disease and con-
gestive heart failure, which might account for hypoxic-
ischemic injury to the hippocampus, although this
remains purely speculative, since these risk factors are
common in individuals of this age without HS [12].
Another case of HSD (P6) with minimal athero-
sclerosis, arteriosclerosis and CAA had a history of
epilepsy, as well as laminar ischemic gliosis in the248 Acta Neuropathol (2007) 113:245–252
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watershed cortices and cortical cystic infarcts and tha-
lamic ischemic gliosis. Epilepsy in this patient was
probably secondary to a porencephalic cyst that was
present in the temporal pole. Given the absence of
degenerative pathology, this case was included in the
HSD group, but presence of extensive cerebrovascular
disease raises the possibility that HS in this case was
related to hypoxic-ischemic injury.
Quantitative and semi-quantitative analyses
Both HSD and FTLD-U HS had severe neuronal loss
in the pyramidal layer of CA1 and the subiculum. No
signiWcant diVerences were found in the severity of
neuronal loss between the two regions; nevertheless,
diVerences in the distribution of neuronal loss were
noted. Most cases had neuronal loss in both CA1 and
the subiculum, except for two cases of HSD that had
isolated CA1 involvement and two cases of FTLD-U
HS that had isolated subicular involvement.
The CA2/3 region and the endplate were not
aVected in most cases. Only cases of HSD occasionally
had neuronal loss in these regions, with involvement of
CA2/3 in P4 and involvement of CA2/3 and endplate in
P6. The dentate was involved in half of the cases of
both groups.
Synaptic loss assessed by image analysis of density
of synaptophysin immunoreactivity was signiWcantly
less in CA1 region in HSD compared to FTLD-U HS
(Fig. 1). A similar trend was noted in the subiculum.
Gliosis as assessed by image analysis with GFAP and
HLA-DR immunostains tended to be greater in HSD
compared with FTLD-U HS (Fig. 1), although it did
not reach statistical signiWcance probably because of
small sample size. Both GFAP and HLA-DR immuno-
reactivity were greater in HSD than in FTLD-U HS in
both CA1 and the subiculum.
There tended to be more corpora amylacea in HSD
than in FTLD-U HS, but this did not reach statistical
signiWcance. A concomitant diagnosis of AGD was
Table 2 Comparison of HSD
and FTLD-U HS
HSD (n = 8) FTLD-U HS 
(n =1 0 )
Age at death (years), mean § Std. Dev. 84 § 56 5 § 12‡
Sex (% of cases)
Male 75 40
Female 25 60
Braak NFT stage, median 
(25%-tile, 75%-tile)
2.25 (1.5, 3) 0 (0, 1)9
Brain weight (g), mean § Std. Dev. 1130 § 100 868 § 130Ð
Gross atrophy (% of cases)
Frontal lobe 25 1009
Medial temporal lobe 13 789
Lateral temporal lobe 33 67
Parietal lobe 17 67
Occipital lobe 13 11
Mammillary bodies 100 100
Hippocampal formation 89 90
Neuronal loss (score), median 
(25%-tile, 75%-tile)
Subiculum 1 (0.25, 1) 1 (1, 1)
CA1 1 (0.75, 1) 1 (0.5, 1)
CA2/3 0 (0, 0.25) 0 (0, 0)
EP 0 (0, 0) 0 (0, 0)
DG 0 (0, 1) 0 (0, 1)
Synaptophysin (% area), mean § SEM
Subiculum 23.4 § 12.3 36.4 § 21.3
CA1 26.5 § 24.4 51.7 § 20.89
GFAP (% area), mean § SEM
Subiculum 9.5 § 7.5 6.2 § 2.9 
CA1 14.9 § 12.5 9.2 § 7.8
HLA-DR (%area), mean § SEM
Subiculum 0.80 § 0.77 0.56 § 0.50
CA1 0.59 § 0.75 0.19 § 0.18
Corpora amylacea (score), median 
(25%-tile, 75%-tile)
1 (0.5, 1.75) 0.5 (0, 2)
Argyrophilic grain disease (% of cases) 13 20
Fisher exact test was used for 
categorical variables, t test for 
continuous variables and 
Mann–Whitney Rank Sum 
test for discontinuous vari-
ables
9 P <0 . 0 5
‡ P <0 . 0 0 1250 Acta Neuropathol (2007) 113:245–252
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made in two cases of FTLD HS and in one case of pure
HS (P6).
Discussion
The present study conWrmed the characteristic Wndings
of neuronal loss and gliosis in CA1 and the subiculum
in HS regardless of etiology; however, there were some
signiWcant diVerences between HSD and HS that
occurs in FTLD-U. In addition, there were subjective
diVerences that did not meet statistical signiWcance
probably related to the small sample size in this study.
The results support the hypothesis that there are diVer-
ences in underlying disease mechanisms in HSD com-
pared to HS in FTLD-U.
From a demographic perspective, demented patients
with HS have been shown to be older than demented
patients without HS [11, 12, 27, 29], although there are
exceptions [2, 10]. Data concerning the age distribution
among patients with HS has to our knowledge not been
reported. In the present study, we show HSD to mainly
aVect the elderly (>80 years of age) as opposed to HS
in FTLD-U. The younger age of the FTLD-U may
account for the lower frequency of concurrent cerebro-
vascular disease, since an age-, sex- and Braak neuroW-
brillary tangle stage-matched cohort had comparable
frequency of cerebrovascular disease.
Microscopically, there were three important diVer-
ences in the pathology in HSD compared with HS in
FTLD-U. First, HSD had lower synaptophysin immu-
noreactivity, suggesting a more destructive process
resulting in more severe synaptic loss, while in FTLD-
U there is selective neuronal loss, but relative preser-
vation of the neuropil, presumably from preserved
aVerent and eVerent projections to sectors that show
neuronal loss. Second, the diVerence in the distribution
of neuronal loss suggested subicular involvement to be
characteristic of HS in FTLD-U. Even though the
diVerences in distribution of neuronal loss did not
reach statistical signiWcance, other observations sup-
port this idea [20]. Third, HSD was associated with
greater astrocytic and microglial reaction compared to
HS in FTLD-U. Glial activation has been proposed to
be caused by neuronal damage, which is present in
both, ischemic and degenerative pathology, but may be
Fig. 1 Comparison of CA1 
region of hippocampus in HS 
associated with FTLD-U (a, c, 
e) and HSD (b, d, f) immuno-
stained for synaptophysin (a, 
b), GFAP (c, d) and HLA-DR 
(e, f). Note better preserva-
tion of neuropil and less glio-
sis in FTLD-U HS compared 
to HSD (All Wgures are £200)Acta Neuropathol (2007) 113:245–252 251
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exacerbated in HSD due to more extensive tissue dam-
age aVecting not only neurons, but also the neuropil.
Macroscopically, FTLD-U HS had more severe cor-
tical atrophy, a not surprising Wnding, since it correlates
with FTLD [25]. HSD on the other hand showed a pat-
tern of atrophy often localized to the hippocampal for-
mation, arguing against this pathology being associated
with more widespread cortical degeneration. This Wts
with results from previous studies of HSD that showed
that loss of synaptophysin immunoreactivity in the hip-
pocampus was not accompanied with similar loss in the
cortex or basal ganglia [12].
Corpora amylacea have been proposed as a possible
marker for hypoxic-ischemic HS, since they may be
numerous in brains of patients exposed to repetitive
hypoxic episodes [1, 6]. They have also been proposed
as a useful marker for evaluating HS in surgical speci-
mens removed for treatment of temporal lobe epilepsy
[9]. Although there was a trend for more corpora amyl-
acea in HSD than in FTLD-U HS, it did not reach sta-
tistical signiWcance, which may be further evidence
against the argument that HSD is due to hypoxic-ische-
mic injury.
Even though we did not Wnd a diVerence in the fre-
quency of AGD in HSD and HS associated with
FTLD-U, the presence of AGD in 3 of the 18 cases,
may suggest an association of HS with AGD as
reported in previous studies [5, 17].
This study included two cases of HSD (P4 and P7) in
which there was not only no evidence of degenerative
pathology, but also no evidence of cerebrovascular
pathology. Cases in which HS is the only pathologic
explanation for dementia are rare. Hattanpa found
some cases of HS to be false negative cases for FTLD-
U after further studying them with ubiquitin immuno-
histochemistry [13]. Since we analyzed our cases with
ubiquitin, false negatives were excluded, giving a prob-
able explanation for the lower prevalence compared to
the 0.48, 0.53 and 2% previously reported by others [2,
15, 27].
The two cases of HSD with neither degenerative nor
cerebrovascular pathology had cardiovascular risk fac-
tors that could link HS to an ischemic condition of sys-
temic origin. They are similar to the ones that have
been reported by others [34, 37]. On the other hand, in
a systematic survey of cardiovascular risk factors,
including electrocardiograph abnormalities, conges-
tive heart failure and cardiomegaly by imaging and
autopsy studies, there was no increased frequency of
these Wndings in HSD compared to age-matched con-
trols without HS [12].
The present study conWrms the Wnding that HS
in the setting of dementia in most cases should be
regarded as a feature linked to a concurrent degenera-
tive disease process, particularly FTLD-U [13, 18, 19,
28]. In other cases, HS may be linked to a systemic
condition (e.g., cardiorespiratory failure) or cerebro-
vascular disease [8, 36]. In rare cases, the etiology is
unknown. The present study suggests that HSD is a
disorder of the elderly that is associated with more
marked neuronal and synaptic loss and greater reactive
gliosis than that seen in HS associated with FTLD-U.
This argues for a diVerent pathogenesis
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